Recently Featured

CDC Halts Testing for Rabies and Pox Viruses

April 11, 2026
The Centers for Disease Control and Prevention (CDC) has officially ceased its testing for rabies and pox viruses, a decision that could have significant implications for public health monitoring and response strategies. This move comes amid ongoing discussions about the adequacy of current surveillance systems and the potential risks associated with emerging infectious diseases. Contextually,…

ACC 2026: Meta-analysis supports CagriSema as superior first-line therapy in obesity

April 11, 2026
A recent meta-analysis presented at ACC 2026 has positioned CagriSema as a superior first-line therapy for obesity, demonstrating enhanced efficacy in weight loss and HbA1c reduction compared to existing treatments. This finding is particularly significant given the growing prevalence of obesity and its associated comorbidities, which have prompted urgent calls for more effective therapeutic options.…

AstraZeneca’s Emerald Program Advances with Imfinzi and Imjudo in Liver Cancer Treatment

April 11, 2026
Another green light appears increasingly within reach for AstraZeneca’s Emerald program after a combination regimen featuring the company’s immunotherapy duo, Imfinzi and Imjudo, demonstrated a significant progression-free survival benefit in patients with locoregional liver cancer. This development marks a pivotal moment for AstraZeneca as it seeks to solidify its position in the oncology market. The…

Eli Lilly Wins FDA Approval for Weight Loss Pill, Tees Up Novo Rivalry

April 11, 2026
Eli Lilly has secured FDA approval for its weight loss medication, Foundayo, positioning the company for potential blockbuster sales in a rapidly growing market. This approval marks a significant milestone for Lilly as it enters a competitive landscape dominated by established players like Novo Nordisk, which has long been a leader in obesity treatments. The…

Ongoing Cases